TITLE

Prostate-Specific Antigen Doubling Time as a Predictor of Gleason Grade in Prostate Cancer

AUTHOR(S)
Nowroozi, Mohammad Reza; Zeighami, Shahryar; Ayati, Mohsen; Jamshidian, Hassan; Ranjbaran, Ali Reza; Moradi, Asaad; Afsar, Firuzeh
PUB. DATE
January 2009
SOURCE
Urology Journal;Jan2009, Vol. 6 Issue 1, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Our aim was to evaluate the value of serum prostate-specific antigen doubling time (PSADT) to differentiate patients with high-grade prostate cancer who require more aggressive therapy from those with low- grade cancer. Materials and Methods: Of 460 patients with extended 12-core transrectal ultrasonography-guided biopsy of the prostate, 59 with confirmed prostate cancer were selected. They had not received any previous treatment for prostate cancer and had at least 2 consecutive serum PSA tests with a rising trend. The PSADT was calculated in patients with 2 serum PSA levels measured with an interval more than 3 months. Results: Of 59 patients with prostate cancer, 35 (59.3%) had low-grade and 24 (40.7%) had high-grade tumors. There was no difference in age between the two groups. The median PSADT in patients with high-grade and low-grade tumors were 12.70 months (range, 0.7 to 44.8 months) and 25.00 months (range, 1.65 to 41.2 months; P = .001). A total of 21 patients with high-grade tumors (87.5%) had a PSADT less than 12 months, while only 9 of those with low-grade tumors (25.7%) had a PSADT less than 12 months. A PSADT cutoff of 12 months provided a sensitivity of 74% and a specificity of 87% for differentiation of high-grade from low-grade cancers. Conclusion: We concluded that men with a short PSADT (< 12 months) were at a higher risk of harboring a high-grade prostate cancer. Our data suggests PSADT can identify patients with high-grade tumors who require more aggressive therapy.
ACCESSION #
40085333

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics